PHILADELPHIA– GSK plc (LSE/NYSE: GSK) today announced the launch of Vaccine Track, a comprehensive platform developed by GSK and IQVIA for use by public health officials, industry leaders and medical professionals to strengthen vaccination data transparency, raise awareness and publicly share vaccination trends to aid improvements in routine adult vaccinations to create healthier communities across the US. This resource will provide frequent and relevant data on trends to focus and enhance public health efforts.
Judy Stewart, GSK Senior Vice President and Head of US Vaccines said: “For the first time, Vaccine Track brings quarterly data tracking and trends together in a comprehensive platform for immunization partners, decision makers and stakeholders. Our goal for Vaccine Track is to support the return to pre-pandemic vaccination rates for adults and to go beyond by empowering the vaccine and public health community with frequently updated, actionable information to get ahead of disease together.”
Collective experience throughout the COVID-19 pandemic has elevated the public’s understanding of the value of vaccines and the importance of data in helping to prevent disease and death, especially in adult and older adult populations. Vaccination rates for CDC-recommended vaccines were low before the pandemic and despite heightened awareness, adult immunization rates significantly declined during the pandemic, compounding already low rates. This is significant because even small drops in immunizations can lead to a resurgence of disease.
“Access to this new set of data, paired with existing data, provides an opportunity for the public health community to work together to increase immunization and prevent disease and death,” said Stewart.
The Vaccine Track platform will enable users to:
- Identify vaccination trends for adults 19+ in the US across multiple vaccines
- Scan immunization claims data nationally and sub-nationally across years
- Track trends based on 2019 pre-COVID-19 baseline vaccination uptake
- Highlight where differences exist based on demographics (e.g., age, race/ethnicity, gender, payer type)
Matthew Guagenty, SVP & GM, Commercial Solutions at IQVIA said: “We are proud to partner with GSK to power Vaccine Track with rich longitudinal data and national-level analytics that we hope will help immunization partners as well as national and local decision-makers and stakeholders work towards solutions to improve vaccination rates. Ultimately, the goal is to improve health outcomes across the nation, including underserved populations.”
Vaccine Track data insights revealed sustained decline of recommended adult immunizations, excluding flu vaccinations, across the US during the pandemic. This was particularly true for minority populations, which already showed lower rates of immunization pre-pandemic.
Temi Folaranmi, MD, Vice President and Vaccines Therapeutic Area Head, US Medical Affairs, GSK said: “Recommended immunization is an essential component of preventive care that protects both individuals and communities from vaccine-preventable disease. Through strengthened data transparency and collaboration, GSK is committed to supporting the public health community in developing long-lasting solutions with key partners. Together, we need to address the challenges to increase vaccination rates and the necessary public policy reforms in order to create healthier communities.”
